We've found
17,797
archived clinical trials in
Peripheral Vascular Disease
We've found
17,797
archived clinical trials in
Peripheral Vascular Disease
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Cardiovascular Inflammation Reduction Trial
Updated: 4/3/2018
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Status: Enrolling
Updated: 4/3/2018
Click here to add this to my saved trials